English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

RESULTS: The high dose prednisone SOC treatment group had a higher proportion 65.2% (15 of 23) of pre-defined events compared to 34.1% (15 of 44) in patients in the combined avacopan treatment groups (p1⁄4 0.02). The greatest differences were seen in the frequencies of psychiatric disorders (26.1% vs 6.8%), hyperglycemia (13.4% vs 2.3%), weight gain>10 kg (8.7% vs 2.3%) and bone fractures or cataracts (each 4.3% vs 0%). Occurrence of new or worsening hypertension was similar across treatment groups (21.7% SOC, 22.7% avacopan). Of note, hypertensive events appeared more rapidly in SOC compared to avacopan groups (median time to onset 8 days for SOC vs 22 and 43 days with avacopan low dose and avacopan no prednisone, respectively), and the need to start or increase anti-hypertensive medication was greater with SOC vs avacopan treatment (100% vs 60%). All adverse events of hypertension were reported as mild or moderate.

FP168GROUP 1 INNATE LYMPHOID CELL INVOLVEMENT IN THE PROGRESSION OF EXPERIMENTAL GLOMERULONEPHRITIS IS INHIBITED BY PPAR-ALPHA